Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Longlive Bio-Technology is a Chinese biotechnology company specializing in the high-value utilization of agricultural waste, specifically corn cobs. The company is a leading producer of functional sugars, including xylo-oligosaccharides (XOS), xylitol, and erythritol, which are used as prebiotics and healthy sweeteners in the food and pharmaceutical industries. Additionally, Longlive developed a biorefinery platform to produce cellulosic ethanol and lignin from biomass. Its operations focused on the integration of functional sugar, starch sugar, and new energy industries. Although once a major player on the Shenzhen Stock Exchange, the company faced severe financial difficulties and was officially delisted in 2020. The company's core technology involves enzymatic hydrolysis and fermentation processes to convert plant fibers into high-value biochemicals.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Longlive Bio-Technology.